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ABSTRACT
Background In the past few years, the occurrence of an oral 
lesion, called osteonecrosis of the jaw, has increasingly been 
reported in patients undergoing treatment with systemic 
bisphosphonates (BPs); however, few papers dealing with oral 
biphosphonates related osteonecrosis of the jaws (BRONJ) can 
be found in the literature. The purpose of the present case was 
to report an occurrence of BRONJ after implant insertion. 
Case report Ten years ago, eight dental implants were inserted 
in the jaw of a 65-year-old female. After 5 years of treatment 
with alendronic acid, a breakdown of the oral mucosa covering 
the implants occurred with a purulent discharge in the left side of 
the jaw; periapical radiolucency was present around both distal 
implants. An en-block resection of the alveolar bone including the 
two implants was performed. Thirthy-five hyperbaric sessions 
were taken and no signs of recurrence of the lesion were observed 
after a follow-up of 20 months. Before the new implant insertion, 
the patient had suspended the treatment with alendronic acid 
for 6 months.  At the interface of one of the implants, a gap was 
observed between bone and implant. This bone was non vital, 
and many osteocyte lacunae were empty. Moreover, this bone 
appeared to be partially demineralized.
Conclusion There is certainly a temporal association between 
oral BPs use and development of BRONJ, but a correlation does 
not necessarily mean causation. In patients undergoing oral 
treatment, clinicians must be aware of the increased risk of 
implant failure.
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inTROduCTiOn
Oral bisphosphonates are commonly prescribed 
for patients with osteoporosis to arrest bone loss 
and preserve bone density. Nitrogen-containing 
bisphosphonates, such as alendronate, risedronate, 
ibandronate, and zoledronate, are agents that inhibit 
bone resorption (1, 2). Recent reports have shown a link 
between these medications and osteonecrosis of the 
jaw, which is a complication resulting in exposed non 
vital maxillary or mandibular bone (3, 4,5,6).
Attempts have recently been made to predict the 
development of bisphosphonate-related osteonecrosis 
of the jaw (BRONJ). Several prospective studies have 
investigated the predictive value of serum levels of 
C-terminal telopeptide of collagen I for the development 
of BRONJ. Despite measurement of serum levels of C- 
terminal telopeptide of collagen I is not a definitive 
predictor of BRONJ, it plays an important role in the risk 
assessment before oral surgery (4). Bisphosphonate-
associated osteonecrosis is a complication that almost 
exclusively affects the jaw bones. As this complication 
has only been recognized within the past 10 years, 
management of patients with biphosphonate- associated 
osteonecrosis is poorly defined. The clinical presentation 
of BRONJ often mimics that of other conditions, such as 
routine dental disease, osteoradionecrosis or avascular 
necrosis; therefore, diagnosis can be difficult. Physicians 
have to choose between continuing the bisphosphonate 
therapy (to reduce the risk of skeletal complications in 
patients with metastatic bone disease or osteoporosis) 
or discontinuing the drug (to possibly improve the odds 
for tissue healing) (7).
The incidence of BRONJ after oral surgery involving 
bone is greater among patients receiving frequent, 
high doses of intravenous biphosphonates than among 
patients taking oral BPs (8). BRONJ seems resistant to 
conventional treatment approaches. Resection of the 
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necrotic bone followed by an adequate wound closure 
is a surgical technique that shows high success rates, 
so patients may benefit from this approach (9). Future 
research should focus on the pathobiological mechanisms 
involved in the development of BRONJ, which could help 
to explain why this complication affects only a small 
number of those who use bisphosphonates, and also 
suggest strategies for prevention and management (7). 
 
CASe RePORT
A 65-year-old woman has been taking oral alendronic 
acid (Fosavance®, MS&D, Whitehousestation, USA) as 
a treatment of postmenopausal osteoporosis disease 
during the last 5 years. The dose of the bisphosponate 
was one tablet of 70 mg once a week. The woman was 
non-smoker and had a good oral hygiene. No other risk 
factors for osteonecrosis were present.
In the first surgery, 10 years ago, eight SteriOss 
(Nobelbiocare, Göteborg, Sweden) implants were placed 
in the mandible in the positions 4.6, 4.5, 4.3, 4.2, 4.1, 
3.1, 3.2, 3.3, 3.5, 3.6 and a screwed implant-supported 
prosthesis was realized.  
After 5 years of oral biphosphonates use, the patient 
referred punching pain, numbness and paresthesia. In 
an oral exploration, sequestrum formation was noted 
at the left side of mandible (Fig. 1). Radiolucency was 
present around both left posterior implants (Fig. 2).
A resection of the alveolar bone including the two distal 
implants was performed under local anesthesia, with deep 
margins in an apparently healthy bone; the flaps were 
accurately sutured. The implants and the surrounding 
tissues were stored immediately after removal in 10% 
neutral buffered formalin. Microscopical analysis of the 
specimens was carried out (Fig. 3).
Osteonecrosis process continued advancing, so five of 
the eight initial implants were lost. Only implants in 
position 3.1, 3.6 and 4.6 survived (Fig. 4, 5).
The histopathological examination of the specimens 
revealed BRONJ. After the surgical resection of affected 
areas and the pharmacological treatment (Amoxiciline 
500 mg/6h + Clorhedixine 0.12%) bone did not achieve 
the adequate level of regeneration; therefore, the patient 
underwent 6-months sessions of hyperbaric camera 
(Naval Hospital, Cartagena, Murcia, Spain). Sessions 
were daily, with a duration of an hour. Moreover, the 
patient underwent a strict clinical and radiological 
follow-up. After the evaluation period, bone remodeling 
of the defects was successful and no signs of recurrence 
of osteonecrosis were detectable.
On postoperative follow-up the wound was well healed 
and X-ray showed good periapical bone remodeling. 
Subsequently, four additional M4 Implants (MIS, Tel 
Aviv Israel) were inserted in the lower jaw (3.3, 3.2, 
4.2, 4.3). Before implant insertion, the patient had 
FIG. 1 sequestrum formation in the mandible; intraoral aspect. FIG. 2 sequestrum formation in mandible; radiographic aspect.
FIG. 3 Tissues resected for microscopic evaluation.  FIG.4  loss of implant 3.6. 17
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suspended the oral biphosphonate treatment for 6 
months after indication of her specialist, and according 
to the approved protocol in use. No preexisting bone 
lesions were present at the preoperative panoramic 
radiography. After 4 months, implants osseointegration 
was successful and prosthetic rehabilitation was carried 
out (Fig. 6).
The histopatological examination was carried out. 
Microscopic analysis of the specimens revealed as 
follows. 
- Fragment 1: the sample corresponded to trabecular 
bone. The main part of the sample was constituted 
by small pieces of bone presenting normal 
characteristics, but surrounded of several necrotic 
focuses with frequent images of “ghost trabecules” 
situated in the centre of wide friables and 
disorganized necrotic areas. 
-  Fragment 2: The other fragment corresponded to 
spongy bone with multiple necrotic areas of irregular 
disposition. Those areas were present in both samples, 
on the edges of them.
Diagnosis was the same for both samples: bone 
fragment with several necrotic areas, in other words, 
bone sequestration.
diSCuSSiOn
Bisphosphonates suppress bone resorption by interfering 
with osteoclast activity. Several of these agents have 
been shown to prevent fractures and increase bone 
mineral density in patients with osteoporosis. Long-
term bisphosphonate therapy has been associated with 
osteonecrosis of the jaw and atypical femur fractures 
(10). Since 2003, there have been flurry of case reports 
and case series suggesting that bisphosphonate use may 
be associated with a condition called ONJ (osteonecrosis 
of the jaw) (11). Recent systematic reviews indicate that 
the use of bisphosphonates for osteoporosis is associated 
with an ONJ incidence of less than 1 in 100,000 patient-
years of exposure (12, 13). ONJ appears to occur most 
often in patients with advanced cancer, particularly 
in those with multiple myeloma or breast cancer, and 
specifically in those undergoing dental procedures (12, 
14). The current definition of ONJ is based on clinical 
findings and includes nonhealing lesions with exposed 
bone, but without evidence of bone necrosis (12, 15).
Many pathogenic factors have been postulated to 
explain how bisphosphonates may play a role in ONJ. 
These include effects on blood supply, angiogenesis, 
excessive bone turnover in jaws leading to increased 
bisphosphonate uptake, excessive suppression by 
bisphosphonates of osteoclastic bone resorption, 
impaired mucosal healing, and use of other drugs (e.g., 
immunosuppressives and glucocorticoids) (16, 17).
Health care providers have been encouraged to advise 
their patients to practice good oral hygiene and have 
regular dental visits. If an invasive dental procedure is 
required, there is no evidence that discontinuation of 
bisphosphonate therapy improves dental outcomes, 
although many guidelines recommend some form of 
interruption (12, 18). 
Ozone therapy had proven efficacy on improving the 
benefits of surgical and pharmacologic treatments, 
favoring the complete healing of the lesions with the 
disappearance of symptoms and even had brought cases 
of lesion progression down to zero. Thus, ozone therapy 
is a reliable option in treatment of ONJ; its benefits are 
remarkable and it improves significantly the outcomes 
of the surgical approach. Into the chamber, patients 
breath compressed air through oronasal mask, tube or 
endotraqueal intubation.
Bisphosphonates exert their therapeutic effects by 
reducing bone resorption, and this leads to a reduction 
in bone remodeling and turnover (19). The degree 
of reduction of bone turnover achieved by each 
bisphosphonate, as well as the duration of action appears 
to be associated with their mineral-binding affinity 
and skeletal retention. Bisphosphonates with higher 
mineral-binding affinity and potential retention, such as 
alendronate and zoledronate, are associated with greater 
reduction of bone turnover and have a longer duration 
of effect after treatment ending. Bisphosphonates with 
 FIG. 6 Final panoramic radiograph after BRONJ treatment and implant 
replacement.
FIG. 5 Remaining implants.18
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lower mineral-binding affinity and retention, such 
as risedronate and etidronate, appear to reduce bone 
turnover less and this effect seems to be more readily 
reversible when therapy stops (2). A recent review of 
the available evidence on long-term efficacy and safety 
of osteoporosis treatments, indicated that it may be 
beneficial to continue osteoporosis therapy indefinitely 
in the majority of patients, with discontinuation of 
treatment in some specific cases, such as need of oral 
surgery. 
COnCLuSiOn
Osteoporosis poses an increased risk of fractures, which 
lead to significant pain, morbidity, functional disability 
and dependence, and mortality. In our opinion, the 
significant positive benefits of bisphosphonates offered 
to patients with osteoporosis outweigh the relatively 
small risk of developing ONJ. Nevertheless, prescribing 
clinicians should understand and recognize this clinical 
entity and fully explain all the benefits and risks of 
bisphosphonate therapy to their patients.
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